Consistent with the expression of mRNA, compared to the control group, evodiamine treatment significantly increased the expression of PTEN, Beclin-1, Bax, caspase-3, and caspase-8 by the concentration-dependent way (P < 0.05, P < 0.01) (Figures 7(b), 7(h), and 7(j)–7(l)) but decreased EGF, EGFR, p-AKT, mTOR, and Bcl-2 both in AGS and BGC-823 cells (P < 0.05, P < 0.01) (Figures 7(c), 7(d), 7(f), 7(g), and 7(i)), indicating that evodiamine could promote the apoptosis of gastric cancer cells. The gene discussed is BCL2; the disease is gastric cancer.